75 million vials of Artesun® (Guilin Pharma’s injectable artesunate) for severe malaria delivered since 2010, saving an estimated additional 450,000–500,000 lives compared to quinine treatment

in 2015, three million children across the Sahel region benefited from Seasonal Malaria Chemoprevention using sulfadoxine-pyrimethamine + amodiaquine, supplied by MMV’s partner Guilin Pharma

17 antimalarial candidates brought forward from discovery research since 2010

1 donor dollar creates $3.5 of investment impact thanks to direct and in-kind support from partners

Pyramax® granules (pyronaridine-artesunate), co-developed with Shin Poong, received positive scientific opinion from the European Medicines Agency via its Article 58 procedure in 2015

400 compounds active against neglected diseases (the Pathogen Box) available for free to researchers

of Coartem® Dispersible (artemether-lumefantrine) for children, co-developed with Novartis and launched in 2009, delivered to over 50 countries

MMV wins Open Data Award for Innovation for its open access Malaria Box

2 dossiers for rectal artesunate suppositories submitted for WHO prequalification by Cipla and Strides

8 new medicines in clinical development prioritizing treatment for vulnerable populations including children and pregnant women, and the ultimate eradication of malaria

18,000 healthcare workers across 2,082 healthcare facilities in sub-Saharan Africa trained to administer injectable artesunate for severe malaria, via CHAI and the Malaria Consortium in the MMV-led Severe Malaria Project

400 partners in 50 countries working with MMV to help defeat malaria